A Multicenter Phase II Study of Enhancement of Immune Reconstitution and Vaccine Responses With Administration of Glyco-Recombinant Human IL-7 in Older Subjects Following Chemotherapy

Trial Profile

A Multicenter Phase II Study of Enhancement of Immune Reconstitution and Vaccine Responses With Administration of Glyco-Recombinant Human IL-7 in Older Subjects Following Chemotherapy

Discontinued
Phase of Trial: Phase II

Latest Information Update: 29 Jun 2016

At a glance

  • Drugs Interleukin-7 (Primary) ; Diphtheria-tetanus vaccine; Hepatitis A vaccine; Hepatitis B vaccine; Influenza virus vaccine; Phi X 174; Pneumococcal vaccine; Poliovirus vaccine
  • Indications Diphtheria; Hepatitis A; Hepatitis B; Influenza virus infections; Pneumococcal infections; Poliomyelitis; Tetanus
  • Focus Pharmacodynamics
  • Most Recent Events

    • 08 Apr 2016 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 04 Nov 2015 Planned number of patients changed from 60 to 50, as reported by ClinicalTrials.gov.
    • 23 Oct 2014 Planned End Date changed from 1 Apr 2015 to 1 Apr 2017 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top